scispace - formally typeset
Open AccessJournal ArticleDOI

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician

TLDR
This review focuses on how evidence from real-world studies can be utilized to complement data from RCTs to gain a more complete picture of the advantages and disadvantages of medications as they are used in practice.
Abstract
Real-world studies have become increasingly important in providing evidence of treatment effectiveness in clinical practice. While randomized clinical trials (RCTs) are the "gold standard" for evaluating the safety and efficacy of new therapeutic agents, necessarily strict inclusion and exclusion criteria mean that trial populations are often not representative of the patient populations encountered in clinical practice. Real-world studies may use information from electronic health and claims databases, which provide large datasets from diverse patient populations, and/or may be observational, collecting prospective or retrospective data over a long period of time. They can therefore provide information on the long-term safety, particularly pertaining to rare events, and effectiveness of drugs in large heterogeneous populations, as well as information on utilization patterns and health and economic outcomes. This review focuses on how evidence from real-world studies can be utilized to complement data from RCTs to gain a more complete picture of the advantages and disadvantages of medications as they are used in practice.Funding: Sanofi US, Inc.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Artificial Intelligence and Machine Learning in Pathology: The Present Landscape of Supervised Methods.

TL;DR: This review provides definitions and basic knowledge of machine learning categories, introduces the underlying concept of the bias-variance trade-off as an important foundation in supervisedMachine learning, and discusses approaches to the supervised machine learning study design.
Journal ArticleDOI

Real-world Performance of the MiniMed™ 780G System: First Report of Outcomes from 4'120 Users.

TL;DR: The MiniMed™ 780G system as discussed by the authors includes an Advanced Hybrid Closed Loop (AHCL) algorithm which provides for both automated basal and correction bolus insulin delivery, and the preliminary performance of the system is shown in Figure 1.
Journal ArticleDOI

Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users

TL;DR: The MiniMed™ 780G system includes an advanced hybrid closed loop (AHCL) algorithm that provides both automated basal and correction bolus insulin delivery in real-world settings as discussed by the authors .
Journal ArticleDOI

Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.

TL;DR: Which antipsychotics and/or mood stabilizers are better for patients with bipolar disorder in the maintenance phase is investigated to investigate which antipsychotic combination therapies are better.
References
More filters
Journal ArticleDOI

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

TL;DR: In patients with type 2 diabetes the risk of diabetic complications was strongly associated with previous hyperglycaemia, with the lowest risk being in those with HbA1c values in the normal range (<6.0%).
Journal ArticleDOI

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

TL;DR: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.
Journal ArticleDOI

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

TL;DR: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.
Journal ArticleDOI

Canagliflozin and cardiovascular and renal events in type 2 diabetes

TL;DR: Patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.
Related Papers (5)